nodes	percent_of_prediction	percent_of_DWPC	metapath
Danazol—PGR—ovarian cancer	0.363	0.613	CbGaD
Danazol—ESR1—ovarian cancer	0.229	0.387	CbGaD
Danazol—CYP19A1—Paclitaxel—ovarian cancer	0.0598	0.58	CbGbCtD
Danazol—CYP3A4—Topotecan—ovarian cancer	0.0153	0.149	CbGbCtD
Danazol—CYP19A1—follicular fluid—ovarian cancer	0.0137	0.13	CbGeAlD
Danazol—CYP3A4—Vinorelbine—ovarian cancer	0.0108	0.105	CbGbCtD
Danazol—PGR—corpus luteum—ovarian cancer	0.00878	0.083	CbGeAlD
Danazol—CYP19A1—corpus luteum—ovarian cancer	0.0079	0.0747	CbGeAlD
Danazol—CYP3A4—Paclitaxel—ovarian cancer	0.00758	0.0735	CbGbCtD
Danazol—PGR—ovarian follicle—ovarian cancer	0.00686	0.0649	CbGeAlD
Danazol—CYP19A1—ovarian follicle—ovarian cancer	0.00618	0.0584	CbGeAlD
Danazol—CYP3A4—Docetaxel—ovarian cancer	0.00548	0.0532	CbGbCtD
Danazol—ESR1—ovarian follicle—ovarian cancer	0.00537	0.0508	CbGeAlD
Danazol—CYP3A4—Doxorubicin—ovarian cancer	0.00409	0.0396	CbGbCtD
Danazol—PGR—oviduct—ovarian cancer	0.00302	0.0285	CbGeAlD
Danazol—AR—oviduct—ovarian cancer	0.0024	0.0227	CbGeAlD
Danazol—ESR1—oviduct—ovarian cancer	0.00236	0.0223	CbGeAlD
Danazol—CCL2—myometrium—ovarian cancer	0.00184	0.0174	CbGeAlD
Danazol—CCL2—embryo—ovarian cancer	0.00177	0.0167	CbGeAlD
Danazol—GNRHR—gonad—ovarian cancer	0.00154	0.0145	CbGeAlD
Danazol—CCL2—epithelium—ovarian cancer	0.00144	0.0136	CbGeAlD
Danazol—CCL2—uterine cervix—ovarian cancer	0.00143	0.0135	CbGeAlD
Danazol—GNRHR—female reproductive system—ovarian cancer	0.00137	0.013	CbGeAlD
Danazol—CCL2—decidua—ovarian cancer	0.00136	0.0129	CbGeAlD
Danazol—CCL2—endometrium—ovarian cancer	0.00129	0.0122	CbGeAlD
Danazol—GNRHR—female gonad—ovarian cancer	0.00125	0.0118	CbGeAlD
Danazol—CCL2—uterus—ovarian cancer	0.00119	0.0113	CbGeAlD
Danazol—GNRHR—testis—ovarian cancer	0.00111	0.0105	CbGeAlD
Danazol—CCL2—female reproductive system—ovarian cancer	0.00107	0.0101	CbGeAlD
Danazol—CCL2—bone marrow—ovarian cancer	0.00101	0.00956	CbGeAlD
Danazol—CCL2—female gonad—ovarian cancer	0.000974	0.00922	CbGeAlD
Danazol—CCL2—vagina—ovarian cancer	0.000968	0.00916	CbGeAlD
Danazol—PGR—myometrium—ovarian cancer	0.000965	0.00913	CbGeAlD
Danazol—CCL2—testis—ovarian cancer	0.000864	0.00817	CbGeAlD
Danazol—AR—myometrium—ovarian cancer	0.000769	0.00727	CbGeAlD
Danazol—PGR—epithelium—ovarian cancer	0.000757	0.00717	CbGeAlD
Danazol—ESR1—myometrium—ovarian cancer	0.000755	0.00714	CbGeAlD
Danazol—SHBG—endometrium—ovarian cancer	0.000754	0.00713	CbGeAlD
Danazol—PGR—uterine cervix—ovarian cancer	0.000751	0.0071	CbGeAlD
Danazol—ESR1—embryo—ovarian cancer	0.000726	0.00687	CbGeAlD
Danazol—PGR—decidua—ovarian cancer	0.000715	0.00677	CbGeAlD
Danazol—SHBG—gonad—ovarian cancer	0.000699	0.00662	CbGeAlD
Danazol—SHBG—uterus—ovarian cancer	0.000695	0.00657	CbGeAlD
Danazol—PGR—endometrium—ovarian cancer	0.000679	0.00643	CbGeAlD
Danazol—CCL2—lymph node—ovarian cancer	0.000626	0.00592	CbGeAlD
Danazol—PGR—uterus—ovarian cancer	0.000626	0.00592	CbGeAlD
Danazol—SHBG—female reproductive system—ovarian cancer	0.000624	0.00591	CbGeAlD
Danazol—CYP19A1—endometrium—ovarian cancer	0.000611	0.00578	CbGeAlD
Danazol—AR—epithelium—ovarian cancer	0.000603	0.00571	CbGeAlD
Danazol—AR—uterine cervix—ovarian cancer	0.000598	0.00566	CbGeAlD
Danazol—ESR1—epithelium—ovarian cancer	0.000592	0.0056	CbGeAlD
Danazol—SHBG—bone marrow—ovarian cancer	0.00059	0.00558	CbGeAlD
Danazol—ESR1—uterine cervix—ovarian cancer	0.000587	0.00556	CbGeAlD
Danazol—Norelgestromin—PGR—ovarian cancer	0.000573	0.107	CrCbGaD
Danazol—AR—decidua—ovarian cancer	0.00057	0.00539	CbGeAlD
Danazol—SHBG—female gonad—ovarian cancer	0.000568	0.00538	CbGeAlD
Danazol—CYP19A1—gonad—ovarian cancer	0.000567	0.00536	CbGeAlD
Danazol—SHBG—vagina—ovarian cancer	0.000565	0.00534	CbGeAlD
Danazol—CYP19A1—uterus—ovarian cancer	0.000563	0.00533	CbGeAlD
Danazol—PGR—female reproductive system—ovarian cancer	0.000563	0.00532	CbGeAlD
Danazol—ESR1—decidua—ovarian cancer	0.00056	0.00529	CbGeAlD
Danazol—Desogestrel—PGR—ovarian cancer	0.000551	0.103	CrCbGaD
Danazol—AR—endometrium—ovarian cancer	0.000541	0.00512	CbGeAlD
Danazol—ESR1—endometrium—ovarian cancer	0.000531	0.00503	CbGeAlD
Danazol—PGR—female gonad—ovarian cancer	0.000512	0.00484	CbGeAlD
Danazol—PGR—vagina—ovarian cancer	0.000509	0.00481	CbGeAlD
Danazol—CYP19A1—female reproductive system—ovarian cancer	0.000506	0.00479	CbGeAlD
Danazol—SHBG—testis—ovarian cancer	0.000504	0.00477	CbGeAlD
Danazol—AR—gonad—ovarian cancer	0.000502	0.00475	CbGeAlD
Danazol—AR—uterus—ovarian cancer	0.000499	0.00472	CbGeAlD
Danazol—ESR1—gonad—ovarian cancer	0.000493	0.00466	CbGeAlD
Danazol—ESR1—uterus—ovarian cancer	0.000489	0.00463	CbGeAlD
Danazol—Quinestrol—ESR1—ovarian cancer	0.000465	0.0869	CrCbGaD
Danazol—CYP19A1—female gonad—ovarian cancer	0.000461	0.00436	CbGeAlD
Danazol—PGR—testis—ovarian cancer	0.000454	0.0043	CbGeAlD
Danazol—AR—female reproductive system—ovarian cancer	0.000448	0.00424	CbGeAlD
Danazol—Etonogestrel—PGR—ovarian cancer	0.000446	0.0834	CrCbGaD
Danazol—ESR1—female reproductive system—ovarian cancer	0.00044	0.00416	CbGeAlD
Danazol—CYP19A1—testis—ovarian cancer	0.000409	0.00387	CbGeAlD
Danazol—AR—female gonad—ovarian cancer	0.000408	0.00386	CbGeAlD
Danazol—AR—vagina—ovarian cancer	0.000405	0.00384	CbGeAlD
Danazol—ESR1—female gonad—ovarian cancer	0.0004	0.00379	CbGeAlD
Danazol—ESR1—vagina—ovarian cancer	0.000398	0.00377	CbGeAlD
Danazol—AR—testis—ovarian cancer	0.000362	0.00342	CbGeAlD
Danazol—ESR1—testis—ovarian cancer	0.000355	0.00336	CbGeAlD
Danazol—Mestranol—ESR1—ovarian cancer	0.000352	0.0659	CrCbGaD
Danazol—Trilostane—ESR1—ovarian cancer	0.000352	0.0659	CrCbGaD
Danazol—Desogestrel—ESR1—ovarian cancer	0.000348	0.0651	CrCbGaD
Danazol—PGR—lymph node—ovarian cancer	0.000329	0.00311	CbGeAlD
Danazol—Levonorgestrel—PGR—ovarian cancer	0.000316	0.059	CrCbGaD
Danazol—CYP19A1—lymph node—ovarian cancer	0.000296	0.0028	CbGeAlD
Danazol—Etonogestrel—ESR1—ovarian cancer	0.000282	0.0527	CrCbGaD
Danazol—AR—lymph node—ovarian cancer	0.000262	0.00248	CbGeAlD
Danazol—ESR1—lymph node—ovarian cancer	0.000257	0.00244	CbGeAlD
Danazol—Norethindrone—PGR—ovarian cancer	0.000256	0.0478	CrCbGaD
Danazol—CYP3A4—female reproductive system—ovarian cancer	0.000246	0.00232	CbGeAlD
Danazol—Weight increased—Paclitaxel—ovarian cancer	0.000243	0.00249	CcSEcCtD
Danazol—Musculoskeletal discomfort—Topotecan—ovarian cancer	0.000241	0.00247	CcSEcCtD
Danazol—Abdominal pain upper—Docetaxel—ovarian cancer	0.000239	0.00246	CcSEcCtD
Danazol—Hypertension—Vinorelbine—ovarian cancer	0.000239	0.00245	CcSEcCtD
Danazol—Paraesthesia—Topotecan—ovarian cancer	0.000237	0.00243	CcSEcCtD
Danazol—Stevens-Johnson syndrome—Paclitaxel—ovarian cancer	0.000236	0.00242	CcSEcCtD
Danazol—Cramp muscle—Docetaxel—ovarian cancer	0.000236	0.00242	CcSEcCtD
Danazol—Urticaria—Chlorambucil—ovarian cancer	0.000236	0.00242	CcSEcCtD
Danazol—Arthralgia—Vinorelbine—ovarian cancer	0.000236	0.00242	CcSEcCtD
Danazol—Musculoskeletal discomfort—Melphalan—ovarian cancer	0.000236	0.00242	CcSEcCtD
Danazol—Acute coronary syndrome—Paclitaxel—ovarian cancer	0.000235	0.00241	CcSEcCtD
Danazol—Body temperature increased—Chlorambucil—ovarian cancer	0.000235	0.00241	CcSEcCtD
Danazol—Myocardial infarction—Paclitaxel—ovarian cancer	0.000234	0.0024	CcSEcCtD
Danazol—Dyspepsia—Topotecan—ovarian cancer	0.000232	0.00238	CcSEcCtD
Danazol—Paraesthesia—Melphalan—ovarian cancer	0.000232	0.00238	CcSEcCtD
Danazol—Fluid retention—Epirubicin—ovarian cancer	0.000231	0.00237	CcSEcCtD
Danazol—Fatigue—Topotecan—ovarian cancer	0.000228	0.00234	CcSEcCtD
Danazol—Dyspepsia—Melphalan—ovarian cancer	0.000228	0.00233	CcSEcCtD
Danazol—Haematuria—Paclitaxel—ovarian cancer	0.000227	0.00233	CcSEcCtD
Danazol—Constipation—Topotecan—ovarian cancer	0.000226	0.00232	CcSEcCtD
Danazol—Fatigue—Melphalan—ovarian cancer	0.000223	0.00229	CcSEcCtD
Danazol—Thrombocytopenia—Vinorelbine—ovarian cancer	0.000221	0.00227	CcSEcCtD
Danazol—Tachycardia—Vinorelbine—ovarian cancer	0.00022	0.00226	CcSEcCtD
Danazol—Haemoglobin—Paclitaxel—ovarian cancer	0.000215	0.00221	CcSEcCtD
Danazol—Fluid retention—Doxorubicin—ovarian cancer	0.000214	0.00219	CcSEcCtD
Danazol—Haemorrhage—Paclitaxel—ovarian cancer	0.000214	0.00219	CcSEcCtD
Danazol—Asthenia—Chlorambucil—ovarian cancer	0.000213	0.00218	CcSEcCtD
Danazol—Pruritus—Chlorambucil—ovarian cancer	0.00021	0.00215	CcSEcCtD
Danazol—Urticaria—Topotecan—ovarian cancer	0.00021	0.00215	CcSEcCtD
Danazol—Body temperature increased—Topotecan—ovarian cancer	0.000209	0.00214	CcSEcCtD
Danazol—Weight increased—Docetaxel—ovarian cancer	0.000206	0.00211	CcSEcCtD
Danazol—Visual impairment—Paclitaxel—ovarian cancer	0.000206	0.00211	CcSEcCtD
Danazol—Musculoskeletal discomfort—Vinorelbine—ovarian cancer	0.000206	0.00211	CcSEcCtD
Danazol—Urticaria—Melphalan—ovarian cancer	0.000205	0.00211	CcSEcCtD
Danazol—Paraesthesia—Vinorelbine—ovarian cancer	0.000203	0.00208	CcSEcCtD
Danazol—Hepatic function abnormal—Epirubicin—ovarian cancer	0.000202	0.00207	CcSEcCtD
Danazol—Erythema multiforme—Paclitaxel—ovarian cancer	0.000202	0.00207	CcSEcCtD
Danazol—Photosensitivity—Epirubicin—ovarian cancer	0.000201	0.00206	CcSEcCtD
Danazol—Stevens-Johnson syndrome—Docetaxel—ovarian cancer	0.0002	0.00205	CcSEcCtD
Danazol—Levonorgestrel—ESR1—ovarian cancer	0.000199	0.0373	CrCbGaD
Danazol—Acute coronary syndrome—Docetaxel—ovarian cancer	0.000199	0.00204	CcSEcCtD
Danazol—Flushing—Paclitaxel—ovarian cancer	0.000198	0.00204	CcSEcCtD
Danazol—Myocardial infarction—Docetaxel—ovarian cancer	0.000198	0.00203	CcSEcCtD
Danazol—Jaundice—Docetaxel—ovarian cancer	0.000197	0.00202	CcSEcCtD
Danazol—Fatigue—Vinorelbine—ovarian cancer	0.000195	0.002	CcSEcCtD
Danazol—Constipation—Vinorelbine—ovarian cancer	0.000193	0.00198	CcSEcCtD
Danazol—Chills—Paclitaxel—ovarian cancer	0.000192	0.00197	CcSEcCtD
Danazol—Fluoxymesterone—ESR1—ovarian cancer	0.00019	0.0355	CrCbGaD
Danazol—Asthenia—Topotecan—ovarian cancer	0.000189	0.00194	CcSEcCtD
Danazol—Alopecia—Paclitaxel—ovarian cancer	0.000189	0.00194	CcSEcCtD
Danazol—Vomiting—Chlorambucil—ovarian cancer	0.000189	0.00193	CcSEcCtD
Danazol—Hepatic function abnormal—Doxorubicin—ovarian cancer	0.000187	0.00192	CcSEcCtD
Danazol—Pruritus—Topotecan—ovarian cancer	0.000187	0.00192	CcSEcCtD
Danazol—Photosensitivity—Doxorubicin—ovarian cancer	0.000186	0.00191	CcSEcCtD
Danazol—Asthenia—Melphalan—ovarian cancer	0.000186	0.0019	CcSEcCtD
Danazol—Pruritus—Melphalan—ovarian cancer	0.000183	0.00188	CcSEcCtD
Danazol—Tension—Paclitaxel—ovarian cancer	0.000183	0.00187	CcSEcCtD
Danazol—Haemoglobin—Docetaxel—ovarian cancer	0.000182	0.00187	CcSEcCtD
Danazol—Haemorrhage—Docetaxel—ovarian cancer	0.000181	0.00186	CcSEcCtD
Danazol—Nervousness—Paclitaxel—ovarian cancer	0.000181	0.00185	CcSEcCtD
Danazol—Back pain—Paclitaxel—ovarian cancer	0.00018	0.00185	CcSEcCtD
Danazol—Urticaria—Vinorelbine—ovarian cancer	0.000179	0.00184	CcSEcCtD
Danazol—Muscle spasms—Paclitaxel—ovarian cancer	0.000179	0.00184	CcSEcCtD
Danazol—Body temperature increased—Vinorelbine—ovarian cancer	0.000179	0.00183	CcSEcCtD
Danazol—Nausea—Chlorambucil—ovarian cancer	0.000176	0.00181	CcSEcCtD
Danazol—Vision blurred—Paclitaxel—ovarian cancer	0.000175	0.0018	CcSEcCtD
Danazol—Visual impairment—Docetaxel—ovarian cancer	0.000175	0.00179	CcSEcCtD
Danazol—Dizziness—Topotecan—ovarian cancer	0.000175	0.00179	CcSEcCtD
Danazol—Tremor—Paclitaxel—ovarian cancer	0.000174	0.00179	CcSEcCtD
Danazol—Migraine—Epirubicin—ovarian cancer	0.000174	0.00178	CcSEcCtD
Danazol—Affect lability—Epirubicin—ovarian cancer	0.000174	0.00178	CcSEcCtD
Danazol—Erythema multiforme—Docetaxel—ovarian cancer	0.000171	0.00176	CcSEcCtD
Danazol—Flushing—Docetaxel—ovarian cancer	0.000168	0.00173	CcSEcCtD
Danazol—Vomiting—Topotecan—ovarian cancer	0.000168	0.00172	CcSEcCtD
Danazol—Ethinyl Estradiol—ESR1—ovarian cancer	0.000168	0.0314	CrCbGaD
Danazol—Mood swings—Epirubicin—ovarian cancer	0.000167	0.00172	CcSEcCtD
Danazol—Vertigo—Paclitaxel—ovarian cancer	0.000167	0.00172	CcSEcCtD
Danazol—Syncope—Paclitaxel—ovarian cancer	0.000167	0.00171	CcSEcCtD
Danazol—Leukopenia—Paclitaxel—ovarian cancer	0.000167	0.00171	CcSEcCtD
Danazol—Rash—Topotecan—ovarian cancer	0.000167	0.00171	CcSEcCtD
Danazol—Dermatitis—Topotecan—ovarian cancer	0.000166	0.00171	CcSEcCtD
Danazol—Headache—Topotecan—ovarian cancer	0.000165	0.0017	CcSEcCtD
Danazol—Palpitations—Paclitaxel—ovarian cancer	0.000165	0.00169	CcSEcCtD
Danazol—Vomiting—Melphalan—ovarian cancer	0.000164	0.00169	CcSEcCtD
Danazol—Loss of consciousness—Paclitaxel—ovarian cancer	0.000164	0.00168	CcSEcCtD
Danazol—Rash—Melphalan—ovarian cancer	0.000163	0.00167	CcSEcCtD
Danazol—Dermatitis—Melphalan—ovarian cancer	0.000163	0.00167	CcSEcCtD
Danazol—Chills—Docetaxel—ovarian cancer	0.000163	0.00167	CcSEcCtD
Danazol—Asthenia—Vinorelbine—ovarian cancer	0.000162	0.00166	CcSEcCtD
Danazol—Abdominal pain upper—Epirubicin—ovarian cancer	0.000161	0.00166	CcSEcCtD
Danazol—Convulsion—Paclitaxel—ovarian cancer	0.000161	0.00165	CcSEcCtD
Danazol—Migraine—Doxorubicin—ovarian cancer	0.000161	0.00165	CcSEcCtD
Danazol—Affect lability—Doxorubicin—ovarian cancer	0.000161	0.00165	CcSEcCtD
Danazol—Hypertension—Paclitaxel—ovarian cancer	0.000161	0.00165	CcSEcCtD
Danazol—Alopecia—Docetaxel—ovarian cancer	0.00016	0.00164	CcSEcCtD
Danazol—Pruritus—Vinorelbine—ovarian cancer	0.00016	0.00164	CcSEcCtD
Danazol—Arthralgia—Paclitaxel—ovarian cancer	0.000159	0.00163	CcSEcCtD
Danazol—Anxiety—Paclitaxel—ovarian cancer	0.000158	0.00162	CcSEcCtD
Danazol—Nausea—Topotecan—ovarian cancer	0.000157	0.00161	CcSEcCtD
Danazol—Mood swings—Doxorubicin—ovarian cancer	0.000155	0.00159	CcSEcCtD
Danazol—Nausea—Melphalan—ovarian cancer	0.000154	0.00158	CcSEcCtD
Danazol—Back pain—Docetaxel—ovarian cancer	0.000153	0.00157	CcSEcCtD
Danazol—Oedema—Paclitaxel—ovarian cancer	0.000152	0.00156	CcSEcCtD
Danazol—Muscle spasms—Docetaxel—ovarian cancer	0.000152	0.00156	CcSEcCtD
Danazol—Eosinophilia—Epirubicin—ovarian cancer	0.000151	0.00155	CcSEcCtD
Danazol—Pancreatitis—Epirubicin—ovarian cancer	0.00015	0.00154	CcSEcCtD
Danazol—Shock—Paclitaxel—ovarian cancer	0.000149	0.00153	CcSEcCtD
Danazol—Dizziness—Vinorelbine—ovarian cancer	0.000149	0.00153	CcSEcCtD
Danazol—Abdominal pain upper—Doxorubicin—ovarian cancer	0.000149	0.00153	CcSEcCtD
Danazol—Progesterone—PGR—ovarian cancer	0.000149	0.0279	CrCbGaD
Danazol—Thrombocytopenia—Paclitaxel—ovarian cancer	0.000149	0.00153	CcSEcCtD
Danazol—Tachycardia—Paclitaxel—ovarian cancer	0.000148	0.00152	CcSEcCtD
Danazol—Hyperhidrosis—Paclitaxel—ovarian cancer	0.000147	0.00151	CcSEcCtD
Danazol—Vomiting—Vinorelbine—ovarian cancer	0.000144	0.00147	CcSEcCtD
Danazol—Rash—Vinorelbine—ovarian cancer	0.000142	0.00146	CcSEcCtD
Danazol—Dermatitis—Vinorelbine—ovarian cancer	0.000142	0.00146	CcSEcCtD
Danazol—Headache—Vinorelbine—ovarian cancer	0.000142	0.00145	CcSEcCtD
Danazol—Syncope—Docetaxel—ovarian cancer	0.000142	0.00145	CcSEcCtD
Danazol—Leukopenia—Docetaxel—ovarian cancer	0.000141	0.00145	CcSEcCtD
Danazol—Eosinophilia—Doxorubicin—ovarian cancer	0.00014	0.00144	CcSEcCtD
Danazol—Palpitations—Docetaxel—ovarian cancer	0.000139	0.00143	CcSEcCtD
Danazol—Photosensitivity reaction—Epirubicin—ovarian cancer	0.000139	0.00143	CcSEcCtD
Danazol—Progesterone—CYP1B1—ovarian cancer	0.000139	0.026	CrCbGaD
Danazol—Weight increased—Epirubicin—ovarian cancer	0.000139	0.00143	CcSEcCtD
Danazol—Loss of consciousness—Docetaxel—ovarian cancer	0.000139	0.00142	CcSEcCtD
Danazol—Pancreatitis—Doxorubicin—ovarian cancer	0.000139	0.00142	CcSEcCtD
Danazol—Musculoskeletal discomfort—Paclitaxel—ovarian cancer	0.000138	0.00142	CcSEcCtD
Danazol—Convulsion—Docetaxel—ovarian cancer	0.000137	0.0014	CcSEcCtD
Danazol—Paraesthesia—Paclitaxel—ovarian cancer	0.000136	0.0014	CcSEcCtD
Danazol—Hypertension—Docetaxel—ovarian cancer	0.000136	0.0014	CcSEcCtD
Danazol—Stevens-Johnson syndrome—Epirubicin—ovarian cancer	0.000135	0.00139	CcSEcCtD
Danazol—Arthralgia—Docetaxel—ovarian cancer	0.000134	0.00138	CcSEcCtD
Danazol—Nausea—Vinorelbine—ovarian cancer	0.000134	0.00138	CcSEcCtD
Danazol—Dyspepsia—Paclitaxel—ovarian cancer	0.000134	0.00137	CcSEcCtD
Danazol—Jaundice—Epirubicin—ovarian cancer	0.000133	0.00136	CcSEcCtD
Danazol—Testosterone—CYP1B1—ovarian cancer	0.000132	0.0246	CrCbGaD
Danazol—Fatigue—Paclitaxel—ovarian cancer	0.000131	0.00134	CcSEcCtD
Danazol—Sweating—Epirubicin—ovarian cancer	0.000131	0.00134	CcSEcCtD
Danazol—Constipation—Paclitaxel—ovarian cancer	0.00013	0.00133	CcSEcCtD
Danazol—Haematuria—Epirubicin—ovarian cancer	0.00013	0.00133	CcSEcCtD
Danazol—Photosensitivity reaction—Doxorubicin—ovarian cancer	0.000129	0.00132	CcSEcCtD
Danazol—Oedema—Docetaxel—ovarian cancer	0.000129	0.00132	CcSEcCtD
Danazol—Weight increased—Doxorubicin—ovarian cancer	0.000129	0.00132	CcSEcCtD
Danazol—Shock—Docetaxel—ovarian cancer	0.000127	0.0013	CcSEcCtD
Danazol—Thrombocytopenia—Docetaxel—ovarian cancer	0.000126	0.00129	CcSEcCtD
Danazol—Tachycardia—Docetaxel—ovarian cancer	0.000126	0.00129	CcSEcCtD
Danazol—Stevens-Johnson syndrome—Doxorubicin—ovarian cancer	0.000125	0.00128	CcSEcCtD
Danazol—Haemoglobin—Epirubicin—ovarian cancer	0.000123	0.00126	CcSEcCtD
Danazol—Jaundice—Doxorubicin—ovarian cancer	0.000123	0.00126	CcSEcCtD
Danazol—Haemorrhage—Epirubicin—ovarian cancer	0.000122	0.00125	CcSEcCtD
Danazol—Sweating—Doxorubicin—ovarian cancer	0.000121	0.00124	CcSEcCtD
Danazol—Urticaria—Paclitaxel—ovarian cancer	0.000121	0.00124	CcSEcCtD
Danazol—Haematuria—Doxorubicin—ovarian cancer	0.00012	0.00123	CcSEcCtD
Danazol—Body temperature increased—Paclitaxel—ovarian cancer	0.00012	0.00123	CcSEcCtD
Danazol—Visual impairment—Epirubicin—ovarian cancer	0.000118	0.00121	CcSEcCtD
Danazol—Musculoskeletal discomfort—Docetaxel—ovarian cancer	0.000117	0.0012	CcSEcCtD
Danazol—Paraesthesia—Docetaxel—ovarian cancer	0.000116	0.00119	CcSEcCtD
Danazol—Erythema multiforme—Epirubicin—ovarian cancer	0.000116	0.00119	CcSEcCtD
Danazol—Haemoglobin—Doxorubicin—ovarian cancer	0.000114	0.00117	CcSEcCtD
Danazol—Flushing—Epirubicin—ovarian cancer	0.000113	0.00116	CcSEcCtD
Danazol—Dyspepsia—Docetaxel—ovarian cancer	0.000113	0.00116	CcSEcCtD
Danazol—Haemorrhage—Doxorubicin—ovarian cancer	0.000113	0.00116	CcSEcCtD
Danazol—Fatigue—Docetaxel—ovarian cancer	0.000111	0.00114	CcSEcCtD
Danazol—Constipation—Docetaxel—ovarian cancer	0.00011	0.00113	CcSEcCtD
Danazol—Chills—Epirubicin—ovarian cancer	0.00011	0.00113	CcSEcCtD
Danazol—Visual impairment—Doxorubicin—ovarian cancer	0.000109	0.00112	CcSEcCtD
Danazol—Asthenia—Paclitaxel—ovarian cancer	0.000109	0.00112	CcSEcCtD
Danazol—Alopecia—Epirubicin—ovarian cancer	0.000108	0.00111	CcSEcCtD
Danazol—Pruritus—Paclitaxel—ovarian cancer	0.000108	0.0011	CcSEcCtD
Danazol—Erythema multiforme—Doxorubicin—ovarian cancer	0.000107	0.0011	CcSEcCtD
Danazol—Flushing—Doxorubicin—ovarian cancer	0.000105	0.00108	CcSEcCtD
Danazol—Tension—Epirubicin—ovarian cancer	0.000104	0.00107	CcSEcCtD
Danazol—Nervousness—Epirubicin—ovarian cancer	0.000103	0.00106	CcSEcCtD
Danazol—Back pain—Epirubicin—ovarian cancer	0.000103	0.00106	CcSEcCtD
Danazol—Muscle spasms—Epirubicin—ovarian cancer	0.000102	0.00105	CcSEcCtD
Danazol—Body temperature increased—Docetaxel—ovarian cancer	0.000102	0.00104	CcSEcCtD
Danazol—Chills—Doxorubicin—ovarian cancer	0.000102	0.00104	CcSEcCtD
Danazol—Dizziness—Paclitaxel—ovarian cancer	0.0001	0.00103	CcSEcCtD
Danazol—Vision blurred—Epirubicin—ovarian cancer	0.0001	0.00103	CcSEcCtD
Danazol—Alopecia—Doxorubicin—ovarian cancer	0.0001	0.00103	CcSEcCtD
Danazol—Tension—Doxorubicin—ovarian cancer	9.66e-05	0.000991	CcSEcCtD
Danazol—Vomiting—Paclitaxel—ovarian cancer	9.66e-05	0.000991	CcSEcCtD
Danazol—Rash—Paclitaxel—ovarian cancer	9.58e-05	0.000983	CcSEcCtD
Danazol—Dermatitis—Paclitaxel—ovarian cancer	9.57e-05	0.000982	CcSEcCtD
Danazol—Nervousness—Doxorubicin—ovarian cancer	9.57e-05	0.000981	CcSEcCtD
Danazol—Vertigo—Epirubicin—ovarian cancer	9.56e-05	0.000981	CcSEcCtD
Danazol—Syncope—Epirubicin—ovarian cancer	9.55e-05	0.000979	CcSEcCtD
Danazol—Leukopenia—Epirubicin—ovarian cancer	9.53e-05	0.000977	CcSEcCtD
Danazol—Back pain—Doxorubicin—ovarian cancer	9.53e-05	0.000977	CcSEcCtD
Danazol—Headache—Paclitaxel—ovarian cancer	9.52e-05	0.000976	CcSEcCtD
Danazol—Muscle spasms—Doxorubicin—ovarian cancer	9.47e-05	0.000971	CcSEcCtD
Danazol—Progesterone—ESR1—ovarian cancer	9.41e-05	0.0176	CrCbGaD
Danazol—Palpitations—Epirubicin—ovarian cancer	9.41e-05	0.000965	CcSEcCtD
Danazol—Loss of consciousness—Epirubicin—ovarian cancer	9.36e-05	0.00096	CcSEcCtD
Danazol—Vision blurred—Doxorubicin—ovarian cancer	9.28e-05	0.000952	CcSEcCtD
Danazol—Asthenia—Docetaxel—ovarian cancer	9.24e-05	0.000948	CcSEcCtD
Danazol—Convulsion—Epirubicin—ovarian cancer	9.22e-05	0.000946	CcSEcCtD
Danazol—Hypertension—Epirubicin—ovarian cancer	9.19e-05	0.000943	CcSEcCtD
Danazol—Pruritus—Docetaxel—ovarian cancer	9.11e-05	0.000935	CcSEcCtD
Danazol—Arthralgia—Epirubicin—ovarian cancer	9.06e-05	0.00093	CcSEcCtD
Danazol—Anxiety—Epirubicin—ovarian cancer	9.03e-05	0.000926	CcSEcCtD
Danazol—Nausea—Paclitaxel—ovarian cancer	9.03e-05	0.000926	CcSEcCtD
Danazol—Vertigo—Doxorubicin—ovarian cancer	8.85e-05	0.000908	CcSEcCtD
Danazol—Syncope—Doxorubicin—ovarian cancer	8.83e-05	0.000906	CcSEcCtD
Danazol—Leukopenia—Doxorubicin—ovarian cancer	8.82e-05	0.000904	CcSEcCtD
Danazol—Palpitations—Doxorubicin—ovarian cancer	8.7e-05	0.000893	CcSEcCtD
Danazol—Oedema—Epirubicin—ovarian cancer	8.69e-05	0.000891	CcSEcCtD
Danazol—Loss of consciousness—Doxorubicin—ovarian cancer	8.66e-05	0.000888	CcSEcCtD
Danazol—Shock—Epirubicin—ovarian cancer	8.55e-05	0.000877	CcSEcCtD
Danazol—Convulsion—Doxorubicin—ovarian cancer	8.53e-05	0.000875	CcSEcCtD
Danazol—Dizziness—Docetaxel—ovarian cancer	8.52e-05	0.000874	CcSEcCtD
Danazol—Thrombocytopenia—Epirubicin—ovarian cancer	8.51e-05	0.000872	CcSEcCtD
Danazol—Hypertension—Doxorubicin—ovarian cancer	8.5e-05	0.000872	CcSEcCtD
Danazol—Tachycardia—Epirubicin—ovarian cancer	8.48e-05	0.00087	CcSEcCtD
Danazol—Hyperhidrosis—Epirubicin—ovarian cancer	8.4e-05	0.000861	CcSEcCtD
Danazol—Arthralgia—Doxorubicin—ovarian cancer	8.38e-05	0.00086	CcSEcCtD
Danazol—Anxiety—Doxorubicin—ovarian cancer	8.36e-05	0.000857	CcSEcCtD
Danazol—Vomiting—Docetaxel—ovarian cancer	8.19e-05	0.00084	CcSEcCtD
Danazol—Rash—Docetaxel—ovarian cancer	8.12e-05	0.000833	CcSEcCtD
Danazol—Dermatitis—Docetaxel—ovarian cancer	8.11e-05	0.000832	CcSEcCtD
Danazol—Headache—Docetaxel—ovarian cancer	8.07e-05	0.000828	CcSEcCtD
Danazol—Oedema—Doxorubicin—ovarian cancer	8.04e-05	0.000825	CcSEcCtD
Danazol—Musculoskeletal discomfort—Epirubicin—ovarian cancer	7.91e-05	0.000812	CcSEcCtD
Danazol—Shock—Doxorubicin—ovarian cancer	7.91e-05	0.000811	CcSEcCtD
Danazol—Thrombocytopenia—Doxorubicin—ovarian cancer	7.87e-05	0.000807	CcSEcCtD
Danazol—Tachycardia—Doxorubicin—ovarian cancer	7.84e-05	0.000805	CcSEcCtD
Danazol—Paraesthesia—Epirubicin—ovarian cancer	7.8e-05	0.0008	CcSEcCtD
Danazol—Hyperhidrosis—Doxorubicin—ovarian cancer	7.77e-05	0.000797	CcSEcCtD
Danazol—Nausea—Docetaxel—ovarian cancer	7.65e-05	0.000785	CcSEcCtD
Danazol—Dyspepsia—Epirubicin—ovarian cancer	7.65e-05	0.000784	CcSEcCtD
Danazol—Fatigue—Epirubicin—ovarian cancer	7.49e-05	0.000768	CcSEcCtD
Danazol—Constipation—Epirubicin—ovarian cancer	7.43e-05	0.000762	CcSEcCtD
Danazol—Musculoskeletal discomfort—Doxorubicin—ovarian cancer	7.32e-05	0.000751	CcSEcCtD
Danazol—Paraesthesia—Doxorubicin—ovarian cancer	7.22e-05	0.00074	CcSEcCtD
Danazol—Ethinyl Estradiol—ABCB1—ovarian cancer	7.13e-05	0.0133	CrCbGaD
Danazol—Dyspepsia—Doxorubicin—ovarian cancer	7.08e-05	0.000726	CcSEcCtD
Danazol—Prednisone—ABCB1—ovarian cancer	6.96e-05	0.013	CrCbGaD
Danazol—Fatigue—Doxorubicin—ovarian cancer	6.93e-05	0.000711	CcSEcCtD
Danazol—Urticaria—Epirubicin—ovarian cancer	6.9e-05	0.000708	CcSEcCtD
Danazol—Constipation—Doxorubicin—ovarian cancer	6.87e-05	0.000705	CcSEcCtD
Danazol—Body temperature increased—Epirubicin—ovarian cancer	6.87e-05	0.000704	CcSEcCtD
Danazol—Norethindrone—ABCB1—ovarian cancer	6.86e-05	0.0128	CrCbGaD
Danazol—Urticaria—Doxorubicin—ovarian cancer	6.39e-05	0.000655	CcSEcCtD
Danazol—Body temperature increased—Doxorubicin—ovarian cancer	6.35e-05	0.000652	CcSEcCtD
Danazol—Asthenia—Epirubicin—ovarian cancer	6.23e-05	0.000639	CcSEcCtD
Danazol—Pruritus—Epirubicin—ovarian cancer	6.15e-05	0.00063	CcSEcCtD
Danazol—Asthenia—Doxorubicin—ovarian cancer	5.77e-05	0.000592	CcSEcCtD
Danazol—Dizziness—Epirubicin—ovarian cancer	5.74e-05	0.000589	CcSEcCtD
Danazol—Pruritus—Doxorubicin—ovarian cancer	5.69e-05	0.000583	CcSEcCtD
Danazol—Vomiting—Epirubicin—ovarian cancer	5.52e-05	0.000567	CcSEcCtD
Danazol—Rash—Epirubicin—ovarian cancer	5.48e-05	0.000562	CcSEcCtD
Danazol—Dermatitis—Epirubicin—ovarian cancer	5.47e-05	0.000561	CcSEcCtD
Danazol—Headache—Epirubicin—ovarian cancer	5.44e-05	0.000558	CcSEcCtD
Danazol—Dizziness—Doxorubicin—ovarian cancer	5.32e-05	0.000545	CcSEcCtD
Danazol—Nausea—Epirubicin—ovarian cancer	5.16e-05	0.000529	CcSEcCtD
Danazol—Vomiting—Doxorubicin—ovarian cancer	5.11e-05	0.000524	CcSEcCtD
Danazol—Rash—Doxorubicin—ovarian cancer	5.07e-05	0.00052	CcSEcCtD
Danazol—Dermatitis—Doxorubicin—ovarian cancer	5.06e-05	0.000519	CcSEcCtD
Danazol—Headache—Doxorubicin—ovarian cancer	5.04e-05	0.000517	CcSEcCtD
Danazol—Hydrocortisone—ABCB1—ovarian cancer	4.91e-05	0.00918	CrCbGaD
Danazol—Nausea—Doxorubicin—ovarian cancer	4.77e-05	0.00049	CcSEcCtD
Danazol—Progesterone—ABCB1—ovarian cancer	4e-05	0.00747	CrCbGaD
Danazol—Testosterone—ABCB1—ovarian cancer	3.78e-05	0.00707	CrCbGaD
Danazol—AR—Integrated Pancreatic Cancer Pathway—PIK3CA—ovarian cancer	2.8e-05	0.000289	CbGpPWpGaD
Danazol—PGR—Signaling Pathways—YAP1—ovarian cancer	2.77e-05	0.000286	CbGpPWpGaD
Danazol—GNRHR—GPCR downstream signaling—PIK3CB—ovarian cancer	2.77e-05	0.000286	CbGpPWpGaD
Danazol—ESR1—Integrated Pancreatic Cancer Pathway—VEGFA—ovarian cancer	2.76e-05	0.000285	CbGpPWpGaD
Danazol—AR—Integrated Breast Cancer Pathway—AKT1—ovarian cancer	2.76e-05	0.000285	CbGpPWpGaD
Danazol—CYP3A4—Biological oxidations—CYP1B1—ovarian cancer	2.76e-05	0.000284	CbGpPWpGaD
Danazol—CCL2—Signaling by GPCR—PIK3CB—ovarian cancer	2.75e-05	0.000284	CbGpPWpGaD
Danazol—CYP3A4—Metapathway biotransformation—CYP1B1—ovarian cancer	2.72e-05	0.00028	CbGpPWpGaD
Danazol—PGR—Signaling Pathways—XIAP—ovarian cancer	2.72e-05	0.00028	CbGpPWpGaD
Danazol—AR—Integrated Pancreatic Cancer Pathway—TP53—ovarian cancer	2.71e-05	0.000279	CbGpPWpGaD
Danazol—GNRHR—GPCR downstream signaling—CXCL8—ovarian cancer	2.66e-05	0.000275	CbGpPWpGaD
Danazol—PGR—Signaling Pathways—SMARCA4—ovarian cancer	2.65e-05	0.000273	CbGpPWpGaD
Danazol—CCL2—Signaling by GPCR—CXCL8—ovarian cancer	2.64e-05	0.000273	CbGpPWpGaD
Danazol—AR—Gene Expression—PARP1—ovarian cancer	2.64e-05	0.000272	CbGpPWpGaD
Danazol—ESR1—Integrated Pancreatic Cancer Pathway—MAPK3—ovarian cancer	2.61e-05	0.000269	CbGpPWpGaD
Danazol—ESR1—Signaling by ERBB4—PIK3CA—ovarian cancer	2.59e-05	0.000267	CbGpPWpGaD
Danazol—PGR—Signaling Pathways—EREG—ovarian cancer	2.59e-05	0.000267	CbGpPWpGaD
Danazol—ESR1—Signaling Pathways—DOK1—ovarian cancer	2.58e-05	0.000266	CbGpPWpGaD
Danazol—GNRHR—GPCR downstream signaling—IL2—ovarian cancer	2.54e-05	0.000262	CbGpPWpGaD
Danazol—ESR1—Integrated Pancreatic Cancer Pathway—MYC—ovarian cancer	2.54e-05	0.000262	CbGpPWpGaD
Danazol—CCL2—Signaling by GPCR—IL2—ovarian cancer	2.53e-05	0.00026	CbGpPWpGaD
Danazol—ESR1—Integrated Breast Cancer Pathway—TP53—ovarian cancer	2.52e-05	0.00026	CbGpPWpGaD
Danazol—CCL2—Signaling Pathways—TERT—ovarian cancer	2.52e-05	0.00026	CbGpPWpGaD
Danazol—GNRHR—Signaling by GPCR—PIK3CB—ovarian cancer	2.52e-05	0.000259	CbGpPWpGaD
Danazol—ESR1—Gene Expression—YAP1—ovarian cancer	2.5e-05	0.000258	CbGpPWpGaD
Danazol—ESR1—Integrated Pancreatic Cancer Pathway—MAPK1—ovarian cancer	2.48e-05	0.000256	CbGpPWpGaD
Danazol—ESR1—Integrated Pancreatic Cancer Pathway—EGFR—ovarian cancer	2.48e-05	0.000256	CbGpPWpGaD
Danazol—ESR1—Signaling Pathways—PPP1CC—ovarian cancer	2.43e-05	0.00025	CbGpPWpGaD
Danazol—GNRHR—Signaling by GPCR—CXCL8—ovarian cancer	2.42e-05	0.000249	CbGpPWpGaD
Danazol—ESR1—Signaling by ERBB4—HRAS—ovarian cancer	2.39e-05	0.000247	CbGpPWpGaD
Danazol—CYP19A1—Integrated Breast Cancer Pathway—AKT1—ovarian cancer	2.37e-05	0.000245	CbGpPWpGaD
Danazol—CYP19A1—Metabolism of lipids and lipoproteins—CAV1—ovarian cancer	2.36e-05	0.000244	CbGpPWpGaD
Danazol—ESR1—Integrated Pancreatic Cancer Pathway—KRAS—ovarian cancer	2.35e-05	0.000242	CbGpPWpGaD
Danazol—CCL2—Signaling Pathways—CAV1—ovarian cancer	2.33e-05	0.00024	CbGpPWpGaD
Danazol—GNRHR—Signaling by GPCR—IL2—ovarian cancer	2.31e-05	0.000238	CbGpPWpGaD
Danazol—GNRHR—Signaling Pathways—TERT—ovarian cancer	2.3e-05	0.000237	CbGpPWpGaD
Danazol—ESR1—Signaling by ERBB4—IL6—ovarian cancer	2.29e-05	0.000236	CbGpPWpGaD
Danazol—AR—Integrated Pancreatic Cancer Pathway—AKT1—ovarian cancer	2.29e-05	0.000236	CbGpPWpGaD
Danazol—PGR—Signaling Pathways—PARP1—ovarian cancer	2.25e-05	0.000232	CbGpPWpGaD
Danazol—CCL2—Signaling Pathways—ESR1—ovarian cancer	2.24e-05	0.000231	CbGpPWpGaD
Danazol—CCL2—Signaling Pathways—IL6ST—ovarian cancer	2.21e-05	0.000228	CbGpPWpGaD
Danazol—ESR1—Gene Expression—PGR—ovarian cancer	2.19e-05	0.000226	CbGpPWpGaD
Danazol—CYP19A1—Metabolism—YAP1—ovarian cancer	2.18e-05	0.000224	CbGpPWpGaD
Danazol—ESR1—Integrated Pancreatic Cancer Pathway—PIK3CA—ovarian cancer	2.16e-05	0.000222	CbGpPWpGaD
Danazol—CYP19A1—Metabolism of lipids and lipoproteins—PIK3CG—ovarian cancer	2.15e-05	0.000222	CbGpPWpGaD
Danazol—PGR—Generic Transcription Pathway—MYC—ovarian cancer	2.15e-05	0.000222	CbGpPWpGaD
Danazol—AR—Gene Expression—PPP2R1A—ovarian cancer	2.14e-05	0.000221	CbGpPWpGaD
Danazol—GNRHR—Signaling Pathways—CAV1—ovarian cancer	2.13e-05	0.00022	CbGpPWpGaD
Danazol—ESR1—Integrated Breast Cancer Pathway—AKT1—ovarian cancer	2.13e-05	0.000219	CbGpPWpGaD
Danazol—CCL2—Signaling Pathways—PIK3CG—ovarian cancer	2.12e-05	0.000219	CbGpPWpGaD
Danazol—CCL2—Signaling Pathways—APC—ovarian cancer	2.12e-05	0.000219	CbGpPWpGaD
Danazol—CCL2—Signaling by GPCR—NRAS—ovarian cancer	2.12e-05	0.000219	CbGpPWpGaD
Danazol—ESR1—Signaling by ERBB4—AKT1—ovarian cancer	2.11e-05	0.000218	CbGpPWpGaD
Danazol—ESR1—Integrated Pancreatic Cancer Pathway—TP53—ovarian cancer	2.09e-05	0.000215	CbGpPWpGaD
Danazol—GNRHR—Signaling Pathways—ESR1—ovarian cancer	2.05e-05	0.000212	CbGpPWpGaD
Danazol—ESR1—Gene Expression—PARP1—ovarian cancer	2.03e-05	0.00021	CbGpPWpGaD
Danazol—CCL2—Signaling by GPCR—MAPK3—ovarian cancer	2.03e-05	0.000209	CbGpPWpGaD
Danazol—GNRHR—Signaling Pathways—IL6ST—ovarian cancer	2.02e-05	0.000208	CbGpPWpGaD
Danazol—PGR—Gene Expression—ESR1—ovarian cancer	1.99e-05	0.000205	CbGpPWpGaD
Danazol—GNRHR—Signaling Pathways—APC—ovarian cancer	1.94e-05	0.0002	CbGpPWpGaD
Danazol—GNRHR—Signaling Pathways—PIK3CG—ovarian cancer	1.94e-05	0.0002	CbGpPWpGaD
Danazol—GNRHR—Signaling by GPCR—NRAS—ovarian cancer	1.94e-05	0.0002	CbGpPWpGaD
Danazol—CCL2—Signaling by GPCR—MAPK1—ovarian cancer	1.93e-05	0.000199	CbGpPWpGaD
Danazol—CCL2—Signaling by GPCR—EGFR—ovarian cancer	1.93e-05	0.000199	CbGpPWpGaD
Danazol—CYP19A1—Metabolism of lipids and lipoproteins—PIK3CD—ovarian cancer	1.89e-05	0.000195	CbGpPWpGaD
Danazol—CCL2—Signaling Pathways—PIK3CD—ovarian cancer	1.86e-05	0.000192	CbGpPWpGaD
Danazol—GNRHR—Signaling by GPCR—MAPK3—ovarian cancer	1.86e-05	0.000192	CbGpPWpGaD
Danazol—ESR1—Signaling Pathways—HDAC6—ovarian cancer	1.84e-05	0.00019	CbGpPWpGaD
Danazol—PGR—Signaling Pathways—PPP2R1A—ovarian cancer	1.83e-05	0.000188	CbGpPWpGaD
Danazol—CCL2—Signaling by GPCR—KRAS—ovarian cancer	1.82e-05	0.000188	CbGpPWpGaD
Danazol—CYP19A1—Metabolism—FASN—ovarian cancer	1.77e-05	0.000183	CbGpPWpGaD
Danazol—GNRHR—Signaling by GPCR—MAPK1—ovarian cancer	1.77e-05	0.000182	CbGpPWpGaD
Danazol—GNRHR—Signaling by GPCR—EGFR—ovarian cancer	1.77e-05	0.000182	CbGpPWpGaD
Danazol—ESR1—Integrated Pancreatic Cancer Pathway—AKT1—ovarian cancer	1.76e-05	0.000182	CbGpPWpGaD
Danazol—CYP19A1—Metabolism—SLC5A5—ovarian cancer	1.74e-05	0.00018	CbGpPWpGaD
Danazol—GNRHR—Signaling Pathways—PIK3CD—ovarian cancer	1.7e-05	0.000176	CbGpPWpGaD
Danazol—GNRHR—GPCR downstream signaling—PIK3CA—ovarian cancer	1.69e-05	0.000174	CbGpPWpGaD
Danazol—CYP19A1—Metabolism—SLC2A1—ovarian cancer	1.68e-05	0.000174	CbGpPWpGaD
Danazol—CYP3A4—Metabolism—NME2—ovarian cancer	1.68e-05	0.000173	CbGpPWpGaD
Danazol—CCL2—Signaling by GPCR—PIK3CA—ovarian cancer	1.68e-05	0.000173	CbGpPWpGaD
Danazol—GNRHR—Signaling by GPCR—KRAS—ovarian cancer	1.67e-05	0.000172	CbGpPWpGaD
Danazol—CYP19A1—Metabolism of lipids and lipoproteins—PIK3CB—ovarian cancer	1.65e-05	0.00017	CbGpPWpGaD
Danazol—ESR1—Gene Expression—PPP2R1A—ovarian cancer	1.65e-05	0.00017	CbGpPWpGaD
Danazol—CCL2—Signaling Pathways—ERBB2—ovarian cancer	1.65e-05	0.00017	CbGpPWpGaD
Danazol—AR—Generic Transcription Pathway—MYC—ovarian cancer	1.64e-05	0.000169	CbGpPWpGaD
Danazol—ESR1—Signaling Pathways—YAP1—ovarian cancer	1.63e-05	0.000168	CbGpPWpGaD
Danazol—CCL2—Signaling Pathways—PIK3CB—ovarian cancer	1.62e-05	0.000168	CbGpPWpGaD
Danazol—CCL2—Signaling Pathways—MTOR—ovarian cancer	1.62e-05	0.000168	CbGpPWpGaD
Danazol—CYP19A1—Metabolism—CYP1B1—ovarian cancer	1.61e-05	0.000167	CbGpPWpGaD
Danazol—ESR1—Signaling Pathways—XIAP—ovarian cancer	1.6e-05	0.000165	CbGpPWpGaD
Danazol—CCL2—Signaling Pathways—CXCL8—ovarian cancer	1.56e-05	0.000161	CbGpPWpGaD
Danazol—ESR1—Signaling Pathways—SMARCA4—ovarian cancer	1.55e-05	0.00016	CbGpPWpGaD
Danazol—CCL2—Signaling by GPCR—HRAS—ovarian cancer	1.55e-05	0.00016	CbGpPWpGaD
Danazol—GNRHR—Signaling by GPCR—PIK3CA—ovarian cancer	1.53e-05	0.000158	CbGpPWpGaD
Danazol—CCL2—Signaling Pathways—CDKN1B—ovarian cancer	1.52e-05	0.000157	CbGpPWpGaD
Danazol—ESR1—Signaling Pathways—EREG—ovarian cancer	1.52e-05	0.000156	CbGpPWpGaD
Danazol—AR—Gene Expression—ESR1—ovarian cancer	1.52e-05	0.000156	CbGpPWpGaD
Danazol—GNRHR—Signaling Pathways—ERBB2—ovarian cancer	1.51e-05	0.000155	CbGpPWpGaD
Danazol—CCL2—Signaling Pathways—CASP3—ovarian cancer	1.49e-05	0.000154	CbGpPWpGaD
Danazol—CCL2—Signaling Pathways—IL2—ovarian cancer	1.49e-05	0.000154	CbGpPWpGaD
Danazol—GNRHR—Signaling Pathways—PIK3CB—ovarian cancer	1.49e-05	0.000153	CbGpPWpGaD
Danazol—GNRHR—Signaling Pathways—MTOR—ovarian cancer	1.49e-05	0.000153	CbGpPWpGaD
Danazol—CCL2—Signaling by GPCR—IL6—ovarian cancer	1.48e-05	0.000153	CbGpPWpGaD
Danazol—CCL2—Signaling Pathways—CCND1—ovarian cancer	1.45e-05	0.00015	CbGpPWpGaD
Danazol—PGR—Signaling Pathways—TERT—ovarian cancer	1.45e-05	0.00015	CbGpPWpGaD
Danazol—CCL2—Signaling Pathways—CTNNB1—ovarian cancer	1.44e-05	0.000149	CbGpPWpGaD
Danazol—CYP19A1—Metabolism—PPP2R1A—ovarian cancer	1.43e-05	0.000148	CbGpPWpGaD
Danazol—GNRHR—Signaling Pathways—CXCL8—ovarian cancer	1.43e-05	0.000147	CbGpPWpGaD
Danazol—CYP19A1—Metabolism of lipids and lipoproteins—PTEN—ovarian cancer	1.43e-05	0.000147	CbGpPWpGaD
Danazol—ESR1—Signaling Pathways—PGR—ovarian cancer	1.42e-05	0.000147	CbGpPWpGaD
Danazol—GNRHR—Signaling by GPCR—HRAS—ovarian cancer	1.42e-05	0.000146	CbGpPWpGaD
Danazol—CCL2—Signaling Pathways—MMP9—ovarian cancer	1.41e-05	0.000146	CbGpPWpGaD
Danazol—CCL2—Signaling Pathways—PTEN—ovarian cancer	1.4e-05	0.000145	CbGpPWpGaD
Danazol—GNRHR—Signaling Pathways—CDKN1B—ovarian cancer	1.39e-05	0.000144	CbGpPWpGaD
Danazol—GNRHR—GPCR downstream signaling—AKT1—ovarian cancer	1.38e-05	0.000142	CbGpPWpGaD
Danazol—CCL2—Signaling by GPCR—AKT1—ovarian cancer	1.37e-05	0.000141	CbGpPWpGaD
Danazol—GNRHR—Signaling Pathways—CASP3—ovarian cancer	1.37e-05	0.000141	CbGpPWpGaD
Danazol—GNRHR—Signaling Pathways—IL2—ovarian cancer	1.36e-05	0.000141	CbGpPWpGaD
Danazol—GNRHR—Signaling by GPCR—IL6—ovarian cancer	1.36e-05	0.00014	CbGpPWpGaD
Danazol—PGR—Signaling Pathways—CAV1—ovarian cancer	1.34e-05	0.000138	CbGpPWpGaD
Danazol—GNRHR—Signaling Pathways—CCND1—ovarian cancer	1.33e-05	0.000137	CbGpPWpGaD
Danazol—CYP19A1—Metabolism—ABCB1—ovarian cancer	1.33e-05	0.000137	CbGpPWpGaD
Danazol—ESR1—Signaling Pathways—PARP1—ovarian cancer	1.32e-05	0.000136	CbGpPWpGaD
Danazol—GNRHR—Signaling Pathways—CTNNB1—ovarian cancer	1.32e-05	0.000136	CbGpPWpGaD
Danazol—CYP19A1—Metabolism—TYMS—ovarian cancer	1.31e-05	0.000135	CbGpPWpGaD
Danazol—PGR—Signaling Pathways—ESR1—ovarian cancer	1.29e-05	0.000133	CbGpPWpGaD
Danazol—GNRHR—Signaling Pathways—MMP9—ovarian cancer	1.29e-05	0.000133	CbGpPWpGaD
Danazol—GNRHR—Signaling Pathways—PTEN—ovarian cancer	1.28e-05	0.000132	CbGpPWpGaD
Danazol—PGR—Signaling Pathways—IL6ST—ovarian cancer	1.27e-05	0.000131	CbGpPWpGaD
Danazol—CCL2—Signaling Pathways—VEGFA—ovarian cancer	1.27e-05	0.000131	CbGpPWpGaD
Danazol—ESR1—Generic Transcription Pathway—MYC—ovarian cancer	1.26e-05	0.00013	CbGpPWpGaD
Danazol—CCL2—Signaling Pathways—STAT3—ovarian cancer	1.26e-05	0.000129	CbGpPWpGaD
Danazol—GNRHR—Signaling by GPCR—AKT1—ovarian cancer	1.25e-05	0.000129	CbGpPWpGaD
Danazol—CCL2—Signaling Pathways—NRAS—ovarian cancer	1.25e-05	0.000129	CbGpPWpGaD
Danazol—PGR—Signaling Pathways—APC—ovarian cancer	1.22e-05	0.000126	CbGpPWpGaD
Danazol—PGR—Signaling Pathways—PIK3CG—ovarian cancer	1.22e-05	0.000126	CbGpPWpGaD
Danazol—CCL2—Signaling Pathways—MAPK3—ovarian cancer	1.2e-05	0.000124	CbGpPWpGaD
Danazol—CCL2—Signaling Pathways—MYC—ovarian cancer	1.17e-05	0.00012	CbGpPWpGaD
Danazol—GNRHR—Signaling Pathways—VEGFA—ovarian cancer	1.16e-05	0.00012	CbGpPWpGaD
Danazol—GNRHR—Signaling Pathways—STAT3—ovarian cancer	1.15e-05	0.000118	CbGpPWpGaD
Danazol—GNRHR—Signaling Pathways—NRAS—ovarian cancer	1.15e-05	0.000118	CbGpPWpGaD
Danazol—CCL2—Signaling Pathways—MAPK1—ovarian cancer	1.14e-05	0.000118	CbGpPWpGaD
Danazol—CCL2—Signaling Pathways—EGFR—ovarian cancer	1.14e-05	0.000118	CbGpPWpGaD
Danazol—GNRHR—Signaling Pathways—MAPK3—ovarian cancer	1.1e-05	0.000113	CbGpPWpGaD
Danazol—CYP3A4—Metabolism—CYTB—ovarian cancer	1.08e-05	0.000112	CbGpPWpGaD
Danazol—CCL2—Signaling Pathways—KRAS—ovarian cancer	1.08e-05	0.000111	CbGpPWpGaD
Danazol—PGR—Signaling Pathways—PIK3CD—ovarian cancer	1.07e-05	0.000111	CbGpPWpGaD
Danazol—ESR1—Signaling Pathways—PPP2R1A—ovarian cancer	1.07e-05	0.000111	CbGpPWpGaD
Danazol—GNRHR—Signaling Pathways—MYC—ovarian cancer	1.07e-05	0.00011	CbGpPWpGaD
Danazol—PGR—Gene Expression—MAPK3—ovarian cancer	1.06e-05	0.00011	CbGpPWpGaD
Danazol—CYP19A1—Metabolism—CAV1—ovarian cancer	1.05e-05	0.000109	CbGpPWpGaD
Danazol—GNRHR—Signaling Pathways—MAPK1—ovarian cancer	1.04e-05	0.000108	CbGpPWpGaD
Danazol—GNRHR—Signaling Pathways—EGFR—ovarian cancer	1.04e-05	0.000108	CbGpPWpGaD
Danazol—PGR—Gene Expression—MYC—ovarian cancer	1.03e-05	0.000107	CbGpPWpGaD
Danazol—CYP19A1—Metabolism of lipids and lipoproteins—PIK3CA—ovarian cancer	1.01e-05	0.000104	CbGpPWpGaD
Danazol—CCL2—Signaling Pathways—PIK3CA—ovarian cancer	9.9e-06	0.000102	CbGpPWpGaD
Danazol—GNRHR—Signaling Pathways—KRAS—ovarian cancer	9.86e-06	0.000102	CbGpPWpGaD
Danazol—CYP19A1—Metabolism—PIK3CG—ovarian cancer	9.59e-06	9.89e-05	CbGpPWpGaD
Danazol—CCL2—Signaling Pathways—TP53—ovarian cancer	9.58e-06	9.88e-05	CbGpPWpGaD
Danazol—PGR—Signaling Pathways—ERBB2—ovarian cancer	9.49e-06	9.79e-05	CbGpPWpGaD
Danazol—CYP3A4—Metabolism—BRIP1—ovarian cancer	9.46e-06	9.76e-05	CbGpPWpGaD
Danazol—CYP3A4—Metabolism—PPP1CC—ovarian cancer	9.46e-06	9.76e-05	CbGpPWpGaD
Danazol—PGR—Signaling Pathways—PIK3CB—ovarian cancer	9.37e-06	9.66e-05	CbGpPWpGaD
Danazol—PGR—Signaling Pathways—MTOR—ovarian cancer	9.37e-06	9.66e-05	CbGpPWpGaD
Danazol—CCL2—Signaling Pathways—HRAS—ovarian cancer	9.16e-06	9.45e-05	CbGpPWpGaD
Danazol—GNRHR—Signaling Pathways—PIK3CA—ovarian cancer	9.06e-06	9.34e-05	CbGpPWpGaD
Danazol—PGR—Signaling Pathways—CXCL8—ovarian cancer	9e-06	9.29e-05	CbGpPWpGaD
Danazol—PGR—Signaling Pathways—CDKN1B—ovarian cancer	8.79e-06	9.07e-05	CbGpPWpGaD
Danazol—CCL2—Signaling Pathways—IL6—ovarian cancer	8.77e-06	9.04e-05	CbGpPWpGaD
Danazol—GNRHR—Signaling Pathways—TP53—ovarian cancer	8.76e-06	9.04e-05	CbGpPWpGaD
Danazol—PGR—Signaling Pathways—CASP3—ovarian cancer	8.62e-06	8.89e-05	CbGpPWpGaD
Danazol—PGR—Signaling Pathways—IL2—ovarian cancer	8.6e-06	8.87e-05	CbGpPWpGaD
Danazol—ESR1—Signaling Pathways—TERT—ovarian cancer	8.52e-06	8.79e-05	CbGpPWpGaD
Danazol—CYP19A1—Metabolism—PIK3CD—ovarian cancer	8.43e-06	8.69e-05	CbGpPWpGaD
Danazol—PGR—Signaling Pathways—CCND1—ovarian cancer	8.39e-06	8.65e-05	CbGpPWpGaD
Danazol—GNRHR—Signaling Pathways—HRAS—ovarian cancer	8.38e-06	8.64e-05	CbGpPWpGaD
Danazol—PGR—Signaling Pathways—CTNNB1—ovarian cancer	8.31e-06	8.57e-05	CbGpPWpGaD
Danazol—PGR—Signaling Pathways—MMP9—ovarian cancer	8.14e-06	8.4e-05	CbGpPWpGaD
Danazol—AR—Gene Expression—MAPK3—ovarian cancer	8.11e-06	8.36e-05	CbGpPWpGaD
Danazol—PGR—Signaling Pathways—PTEN—ovarian cancer	8.1e-06	8.35e-05	CbGpPWpGaD
Danazol—CCL2—Signaling Pathways—AKT1—ovarian cancer	8.09e-06	8.34e-05	CbGpPWpGaD
Danazol—GNRHR—Signaling Pathways—IL6—ovarian cancer	8.02e-06	8.27e-05	CbGpPWpGaD
Danazol—AR—Gene Expression—MYC—ovarian cancer	7.88e-06	8.13e-05	CbGpPWpGaD
Danazol—ESR1—Signaling Pathways—CAV1—ovarian cancer	7.88e-06	8.13e-05	CbGpPWpGaD
Danazol—ESR1—Signaling Pathways—IL6ST—ovarian cancer	7.47e-06	7.7e-05	CbGpPWpGaD
Danazol—GNRHR—Signaling Pathways—AKT1—ovarian cancer	7.4e-06	7.63e-05	CbGpPWpGaD
Danazol—CYP19A1—Metabolism—PIK3CB—ovarian cancer	7.35e-06	7.58e-05	CbGpPWpGaD
Danazol—PGR—Signaling Pathways—VEGFA—ovarian cancer	7.31e-06	7.54e-05	CbGpPWpGaD
Danazol—PGR—Signaling Pathways—STAT3—ovarian cancer	7.24e-06	7.47e-05	CbGpPWpGaD
Danazol—PGR—Signaling Pathways—NRAS—ovarian cancer	7.22e-06	7.45e-05	CbGpPWpGaD
Danazol—ESR1—Signaling Pathways—PIK3CG—ovarian cancer	7.18e-06	7.4e-05	CbGpPWpGaD
Danazol—ESR1—Signaling Pathways—APC—ovarian cancer	7.18e-06	7.4e-05	CbGpPWpGaD
Danazol—PGR—Gene Expression—AKT1—ovarian cancer	7.18e-06	7.4e-05	CbGpPWpGaD
Danazol—PGR—Signaling Pathways—MAPK3—ovarian cancer	6.92e-06	7.13e-05	CbGpPWpGaD
Danazol—PGR—Signaling Pathways—MYC—ovarian cancer	6.73e-06	6.94e-05	CbGpPWpGaD
Danazol—PGR—Signaling Pathways—MAPK1—ovarian cancer	6.58e-06	6.79e-05	CbGpPWpGaD
Danazol—PGR—Signaling Pathways—EGFR—ovarian cancer	6.58e-06	6.79e-05	CbGpPWpGaD
Danazol—CYP3A4—Metabolism—YAP1—ovarian cancer	6.35e-06	6.55e-05	CbGpPWpGaD
Danazol—CYP19A1—Metabolism—PTEN—ovarian cancer	6.35e-06	6.55e-05	CbGpPWpGaD
Danazol—ESR1—Signaling Pathways—PIK3CD—ovarian cancer	6.31e-06	6.51e-05	CbGpPWpGaD
Danazol—ESR1—Gene Expression—MAPK3—ovarian cancer	6.24e-06	6.44e-05	CbGpPWpGaD
Danazol—PGR—Signaling Pathways—KRAS—ovarian cancer	6.22e-06	6.41e-05	CbGpPWpGaD
Danazol—ESR1—Gene Expression—MYC—ovarian cancer	6.07e-06	6.26e-05	CbGpPWpGaD
Danazol—PGR—Signaling Pathways—PIK3CA—ovarian cancer	5.71e-06	5.89e-05	CbGpPWpGaD
Danazol—ESR1—Signaling Pathways—ERBB2—ovarian cancer	5.57e-06	5.75e-05	CbGpPWpGaD
Danazol—PGR—Signaling Pathways—TP53—ovarian cancer	5.53e-06	5.7e-05	CbGpPWpGaD
Danazol—ESR1—Signaling Pathways—MTOR—ovarian cancer	5.5e-06	5.67e-05	CbGpPWpGaD
Danazol—ESR1—Signaling Pathways—PIK3CB—ovarian cancer	5.5e-06	5.67e-05	CbGpPWpGaD
Danazol—AR—Gene Expression—AKT1—ovarian cancer	5.47e-06	5.64e-05	CbGpPWpGaD
Danazol—ESR1—Signaling Pathways—CXCL8—ovarian cancer	5.28e-06	5.45e-05	CbGpPWpGaD
Danazol—PGR—Signaling Pathways—HRAS—ovarian cancer	5.28e-06	5.45e-05	CbGpPWpGaD
Danazol—CYP3A4—Metabolism—FASN—ovarian cancer	5.17e-06	5.34e-05	CbGpPWpGaD
Danazol—ESR1—Signaling Pathways—CDKN1B—ovarian cancer	5.16e-06	5.32e-05	CbGpPWpGaD
Danazol—CYP3A4—Metabolism—SLC5A5—ovarian cancer	5.09e-06	5.25e-05	CbGpPWpGaD
Danazol—ESR1—Signaling Pathways—CASP3—ovarian cancer	5.06e-06	5.22e-05	CbGpPWpGaD
Danazol—PGR—Signaling Pathways—IL6—ovarian cancer	5.06e-06	5.22e-05	CbGpPWpGaD
Danazol—ESR1—Signaling Pathways—IL2—ovarian cancer	5.05e-06	5.21e-05	CbGpPWpGaD
Danazol—ESR1—Signaling Pathways—CCND1—ovarian cancer	4.92e-06	5.08e-05	CbGpPWpGaD
Danazol—CYP3A4—Metabolism—SLC2A1—ovarian cancer	4.92e-06	5.07e-05	CbGpPWpGaD
Danazol—ESR1—Signaling Pathways—CTNNB1—ovarian cancer	4.88e-06	5.03e-05	CbGpPWpGaD
Danazol—ESR1—Signaling Pathways—MMP9—ovarian cancer	4.78e-06	4.93e-05	CbGpPWpGaD
Danazol—ESR1—Signaling Pathways—PTEN—ovarian cancer	4.75e-06	4.9e-05	CbGpPWpGaD
Danazol—CYP3A4—Metabolism—CYP1B1—ovarian cancer	4.71e-06	4.86e-05	CbGpPWpGaD
Danazol—PGR—Signaling Pathways—AKT1—ovarian cancer	4.67e-06	4.81e-05	CbGpPWpGaD
Danazol—CYP19A1—Metabolism—PIK3CA—ovarian cancer	4.48e-06	4.62e-05	CbGpPWpGaD
Danazol—ESR1—Signaling Pathways—VEGFA—ovarian cancer	4.29e-06	4.43e-05	CbGpPWpGaD
Danazol—ESR1—Signaling Pathways—STAT3—ovarian cancer	4.25e-06	4.38e-05	CbGpPWpGaD
Danazol—ESR1—Signaling Pathways—NRAS—ovarian cancer	4.24e-06	4.37e-05	CbGpPWpGaD
Danazol—ESR1—Gene Expression—AKT1—ovarian cancer	4.21e-06	4.34e-05	CbGpPWpGaD
Danazol—CYP3A4—Metabolism—PPP2R1A—ovarian cancer	4.18e-06	4.31e-05	CbGpPWpGaD
Danazol—ESR1—Signaling Pathways—MAPK3—ovarian cancer	4.06e-06	4.19e-05	CbGpPWpGaD
Danazol—ESR1—Signaling Pathways—MYC—ovarian cancer	3.95e-06	4.07e-05	CbGpPWpGaD
Danazol—CYP3A4—Metabolism—ABCB1—ovarian cancer	3.88e-06	4e-05	CbGpPWpGaD
Danazol—ESR1—Signaling Pathways—MAPK1—ovarian cancer	3.86e-06	3.98e-05	CbGpPWpGaD
Danazol—ESR1—Signaling Pathways—EGFR—ovarian cancer	3.86e-06	3.98e-05	CbGpPWpGaD
Danazol—CYP3A4—Metabolism—TYMS—ovarian cancer	3.81e-06	3.93e-05	CbGpPWpGaD
Danazol—CYP19A1—Metabolism—AKT1—ovarian cancer	3.66e-06	3.77e-05	CbGpPWpGaD
Danazol—ESR1—Signaling Pathways—KRAS—ovarian cancer	3.65e-06	3.76e-05	CbGpPWpGaD
Danazol—ESR1—Signaling Pathways—PIK3CA—ovarian cancer	3.35e-06	3.46e-05	CbGpPWpGaD
Danazol—ESR1—Signaling Pathways—TP53—ovarian cancer	3.24e-06	3.34e-05	CbGpPWpGaD
Danazol—ESR1—Signaling Pathways—HRAS—ovarian cancer	3.1e-06	3.2e-05	CbGpPWpGaD
Danazol—CYP3A4—Metabolism—CAV1—ovarian cancer	3.07e-06	3.17e-05	CbGpPWpGaD
Danazol—ESR1—Signaling Pathways—IL6—ovarian cancer	2.97e-06	3.06e-05	CbGpPWpGaD
Danazol—CYP3A4—Metabolism—PIK3CG—ovarian cancer	2.8e-06	2.89e-05	CbGpPWpGaD
Danazol—ESR1—Signaling Pathways—AKT1—ovarian cancer	2.74e-06	2.82e-05	CbGpPWpGaD
Danazol—CYP3A4—Metabolism—PIK3CD—ovarian cancer	2.46e-06	2.54e-05	CbGpPWpGaD
Danazol—CYP3A4—Metabolism—PIK3CB—ovarian cancer	2.14e-06	2.21e-05	CbGpPWpGaD
Danazol—CYP3A4—Metabolism—PTEN—ovarian cancer	1.85e-06	1.91e-05	CbGpPWpGaD
Danazol—CYP3A4—Metabolism—PIK3CA—ovarian cancer	1.31e-06	1.35e-05	CbGpPWpGaD
Danazol—CYP3A4—Metabolism—AKT1—ovarian cancer	1.07e-06	1.1e-05	CbGpPWpGaD
